Application of purgation-stopping capsule in preparation of medicine for treating leukemia
The drug prepared by using Xie Ting Feng capsules solved the problem of poor efficacy in existing leukemia treatments, achieved inhibition and apoptosis induction of leukemia cells, improved the condition of leukemia mice, and demonstrated its potential in the treatment of leukemia.
Patent Information
- Application Number
- CN202511823971.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-05
- Publication Date
- 2026-02-06
AI Technical Summary
Existing leukemia treatments are not very effective, and there is an urgent need for highly effective and low-toxicity drugs to improve patients' survival rates and quality of life.
Using Xietingfeng capsules as a natural drug resource, a drug was prepared to inhibit the activity of leukemia cells, inhibit cell proliferation, and induce cell apoptosis. Its inhibitory and therapeutic effects on leukemia cells were verified through in vitro and in vivo experiments.
Xie Ting Feng capsules can significantly inhibit the vitality and proliferation of leukemia cells, induce apoptosis, improve the spleen structure of leukemia mice, reduce the burden on the spleen, increase hematocrit, and reduce the expression of CD71+ cell population, showing potential as a drug for the prevention and treatment of leukemia.
Smart Images
Figure CN121466176A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The application belongs to the technical field of biology and medicine, and particularly relates to application of Xiesheng capsules in preparation of a drug for treating leukemia. BACKGROUND
[0002] Leukemia is a kind of malignant clonal disease of hematopoietic stem cells. It is mainly divided into acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). At present, the main treatment scheme for leukemia is chemotherapy, targeted therapy, immunotherapy and stem cell transplantation, etc., but the treatment effect is far from optimistic, and it is urgent to improve the early diagnosis rate and excavate high-efficiency and low-toxicity treatment drugs, which is a key way to treat and improve the survival rate of leukemia patients and improve the life quality of patients.
[0003] Xiesheng capsules have the effects of clearing heat and resolving toxins, drying dampness and stopping diarrhea. They are used for diarrhea, dysentery, food injury and diarrhea, abdominal pain, halitosis, belching and acute and chronic enteritis. The main components include four medicinal materials of Fagara, Sophora, Dandelion and Mahonia. The product is a capsule, and the content is brownish yellow to brownish granules and powder; the smell is weak, and the taste is bitter. No report has been found about the effect of Xiesheng capsules on treating leukemia and its mechanism. SUMMARY
[0004] The purpose of the application is to find new natural drug resources with high efficiency and low toxicity for treating leukemia, improve the survival rate of leukemia patients and improve the life quality of patients.
[0005] In order to achieve the above purpose, the application provides application of Xiesheng capsules in preparation of a drug for treating leukemia, and the leukemia is any one or more of acute lymphoblastic leukemia, acute myeloid leukemia and chronic myeloid leukemia. The application simultaneously reflects the new effect of Xiesheng capsules and the important role of new use of old drugs.
[0006] The aforementioned drugs for treating leukemia include any one or more of the following: drugs that inhibit leukemia cell viability, drugs that inhibit leukemia cell proliferation, and drugs that induce leukemia cell apoptosis. Specifically, the leukemia cells in the drugs that inhibit leukemia cell viability include any one or more of human acute myeloid leukemia cells (KG-1a), human erythroleukemia cells (HEL), human chronic myeloid leukemia cells in the blast crisis phase (K562), and human acute T-lymphocytic leukemia cells (Jurkat); the leukemia cells in the drugs that induce leukemia cell apoptosis and drugs that inhibit leukemia cell proliferation are primarily human erythroleukemia cells (HEL).
[0007] In vitro, this invention uses the MTT assay to determine the half-maximal inhibitory concentration (IC50) of Xietingfeng capsules against different leukemia cell lines HEL, K562, KG-1a, and Jurkat. 50 In vitro, the inhibitory rate of Xietingfeng capsules on human erythroleukemia cells (HEL) at 24 h, 48 h, and 72 h was detected using the MTT assay. Morphological changes in HEL cells at 24 h, 48 h, and 72 h were observed using an inverted microscope. Flow cytometry was used to detect cell cycle arrest and apoptosis rates of HEL cells at 48 h and 72 h after treatment with serum containing Xietingfeng capsules. The results showed that Xietingfeng capsules inhibited the proliferation of leukemia cells (HEL, KG-1a, K562, and Jurkat), induced apoptosis in HEL cells, and arrested the HEL cell cycle at the G1 phase. This demonstrates that Xietingfeng capsules have a good effect on HEL cells in human erythroleukemia cells. In vivo experiments further demonstrated that Xie Ting Feng capsules can improve the spleen structure in leukemia mice, reduce the burden on the spleen, increase hematocrit, and reduce CD71 levels. + Expression of cell populations promotes the transformation of immature cells into Ter119. + Cell population differentiation, and thus effective treatment of leukemia mice, demonstrates the significant potential of Xietingfeng capsules in the prevention and treatment of leukemia.
[0008] This invention allows for the direct preparation of Xietingfeng capsules into a drug for treating leukemia, or its combination with other drugs for treating leukemia into a compound preparation, or its preparation with a pharmaceutically acceptable carrier into a drug for treating leukemia. The drug is prepared in pharmaceutically permissible oral or injectable dosage forms, or in dosage forms manufactured using modern technology.
[0009] The beneficial effects of this invention are as follows: 1. Compared with the existing uses of Xietingfeng capsules, the present invention has discovered a new efficacy of Xietingfeng capsules in the prevention and treatment of leukemia, and it has the potential to become a drug for the prevention and treatment of leukemia.
[0010] 2. Xiachiengao capsule has been used in clinic, with low toxicity, can effectively shorten the preclinical research, and has good application prospect.
[0011] 3. Xiachiengao capsule can inhibit leukemia cell viability, inhibit leukemia cell proliferation, block leukemia cell cycle, induce leukemia cell apoptosis and effectively treat leukemia mice, which has important prospect to improve the survival rate of leukemia patients and improve the life quality of patients. BRIEF DESCRIPTION OF DRAWINGS
[0012] Figure 1 Fig. 1 is the 72 h half-inhibitory concentration (IC50) of different concentrations of Xiachiengao capsule on different leukemia cells HEL, K562, KG-1a, Jurkat and human normal liver cells HL-7702 detected by MTT method. 50 Fig. 2 is the inhibition rate of Xiachiengao capsule on human erythroleukemia cells HEL 24 h, 48 h, 72 h.
[0013] Figure 2 Fig. 3 is the morphological changes of human erythroleukemia cells HEL 48 h, 72 h treated with different concentrations of Xiachiengao capsule rat drug-containing serum (XTFs) (magnification 200 times, scale 100 μm).
[0014] Figure 3 Fig. 4 is the survival rate of human erythroleukemia cells HEL 48 h, 72 h treated with different concentrations of Xiachiengao capsule rat drug-containing serum (XTFs).
[0015] Figure 4 Fig. 5 is the apoptosis rate of human erythroleukemia cells HEL 48 h, 72 h treated with different concentrations of Xiachiengao capsule rat drug-containing serum (XTFs) detected by flow cytometry.
[0016] Figure 5 Fig. 6 is the liver and kidney function detection of each group of mice. A is alanine aminotransferase (ALT) of liver function; B is aspartate aminotransferase (AST) of liver function; C is urea (UREA) of kidney function.
[0017] Figure 6A is the comparison of spleen of each group of mice; B is the weight statistics of spleen of each group of mice; C is the blood volume ratio statistics of each group of mice; D, E, F and G are the comparison of liver, lung, heart and kidney weight of mice, respectively.
[0018] Figure 7 A is the comparison of spleen of each group of mice; B is the weight statistics of spleen of each group of mice; C is the blood volume ratio statistics of each group of mice; D, E, F and G are the comparison of liver, lung, heart and kidney weight of mice, respectively. + and Ter119 + cell population expression changes. Wherein A is the expression of CD71 + and Ter119 + cell population in spleen of leukemia mice treated by Xiacheng Capsule detected by flow cytometry; B is the statistical chart of CD71 + and Ter119 + cell population expression in spleen, respectively.
[0019] Figure 8 A is the comparison of spleen of each group of mice; B is the weight statistics of spleen of each group of mice; C is the blood volume ratio statistics of each group of mice; D, E, F and G are the comparison of liver, lung, heart and kidney weight of mice, respectively. + and Ter119 + cell population expression changes. Wherein A is the expression of CD71 + and Ter119 + cell population in bone marrow of leukemia mice treated by Xiacheng Capsule detected by flow cytometry; B is the statistical chart of CD71 + and Ter119 + cell population expression in bone marrow, respectively.
[0020] Figure 9 A is the comparison of spleen of each group of mice; B is the weight statistics of spleen of each group of mice; C is the blood volume ratio statistics of each group of mice; D, E, F and G are the comparison of liver, lung, heart and kidney weight of mice, respectively. DETAILED DESCRIPTION
[0021] The application will be further described in detail below in combination with examples and drawings, but the protection scope of the application is not limited to these examples. Example 1
[0022] Experimental materials: RPMI-1640 and DMEM medium, fetal bovine serum (FBS) were purchased from Gibco Company of the United States; streptomycin-aztreonam mixture (100x) was purchased from Hyclone Company of the United States; apoptosis kit was purchased from BD Company of the United States; iodinated propylidene (PI) was purchased from China Biyun Tian Company; MTT and Triton X-100 were purchased from Beijing Solaybao; RNase A was purchased from Dalian Baobiology; Xieping Sealing Capsules were purchased from Guizhou Bailin Enterprise Group Pharmaceutical Co., Ltd.; SD male rats and Balb / c mice were purchased from Chongqing Tengxin Huafu Experimental Animal Sales Co., Ltd.; vincristine was purchased from Shenzhen Wanle Pharmaceutical Co., Ltd.; NIH3T3 cells (expressing F-MuLV clone 57 vector) were donated by Professor Ben-David Yaacov of Guizhou Province Natural Products Research Center; Ter119 antibody was purchased from BD Company of the United States; CD71 antibody was purchased from Thermo Fisher Company of the United States; human red and white blood cell HEL, human chronic myeloid leukemia cell K562, human acute myeloid leukemia cell KG-1a, human acute T lymphoblastic leukemia cell Jurkat and human normal liver cell HL-7702 were purchased from American Type Culture Collection (ATCC).
[0023] Preparation of Xieping Sealing Capsule (XTF) mother liquor: Take the content of Xieping Sealing Capsule, dissolve it in 60% volume concentration of ethanol aqueous solution, shake for 1 h on a shaking table, ultrasonic for 40 min, filter twice with absorbent cotton, remove ethanol from the filtrate by rotary evaporation, remove water at-80℃ overnight, and obtain a powder sample by freeze-drying; prepare the powder sample into a 100 mg / mL mother liquor with normal saline, and store it at-20℃.
[0024] Preparation of 5% MTT solution: weigh 0.5 g of MTT powder, add 100 mL of sterilized PBS buffer, dissolve at 60℃, filter sterilization with 0.22 μm microporous filter membrane, and store at-20℃.
[0025] Preparation of rat serum containing Xie Ting Se capsule (XTFs): 30 healthy male SD rats with a body weight of 200 ± 10 g were randomly divided into normal control group (NC group) and Xie Ting Se capsule group. Xie Ting Se capsule was prepared into a suspension with normal saline, and the dosage was 620 mg / kg, and the volume was 1 mL / 100 g of rat body weight. The NC group was given the same volume of normal saline at the same time. Once a day, continuous gavage for 5 days. After the 4th administration, the rats were fasted (without water) for 12 hours, and 2 hours after the 5th administration, they were anesthetized with tri- bromoethanol (0.3 mL / 100 g of body weight) intraperitoneally. After the rats were anesthetized, they were fixed on the operating table, and blood was collected from the abdominal aorta and collected in a coagulation tube. The whole blood was left at room temperature for 1-2 hours, and after natural coagulation, it was centrifuged at 3500 rpm for 15 min, and the supernatant was carefully aspirated to obtain the drug-containing serum. Then, the serum was placed in a 56°C water bath for 30 min, and then filtered through a 0.22 μm microporous filter to remove bacteria. Finally, the sterile drug-containing serum was aliquoted and stored at -80°C or -20°C refrigerator for standby.
[0026] Triple liquid preparation: Take SDS 10 g, add less than 95 mL of double distilled water to dissolve it thoroughly, then add isopropyl alcohol 5 mL, and then add double distilled water to 100 mL. Finally, add 100 μL of hydrochloric acid.
[0027] Cell culture: After the cells HEL, K562, Jurkat, KG-1a were recovered, they were cultured in a 37°C, 5% CO2 incubator with RPMI-1640 medium containing 10% FBS. After the cells HL-7702 were recovered, they were cultured in a 37°C, 5% CO2 incubator with DMEM medium containing 10% FBS.
[0028] 1. Cell viability detection Different leukemia cell lines in the logarithmic growth phase (HEL, K562, KG-1a, and Jurkat) were diluted in RPMI-1640 medium containing a mixture of 10% FBS and 1% penicillin-streptomycin. Human normal hepatocytes (HL-7702) were diluted in DMEM medium containing a mixture of 10% FBS and 1% penicillin-streptomycin. Cells were seeded at a density of 8000 cells / well in 96-well plates (90 μL per well). After incubation at 37°C and 5% CO2 for 4 h, 10 μL of a drug-eluting capsule solution was added to each well as a treatment group (concentrations of 0.63 mg / mL, 1.25 mg / mL, 2.50 mg / mL, 5.00 mg / mL, and 10.00 mg / mL, respectively, diluted with serum-free RPMI-1640 medium). A control group (NC) was also included, with 10 μL of serum-free RPMI-1640 medium added to each well. Each group had three replicates. The plates were incubated at 37°C and 5% CO2 for 4 h. After culturing in a CO2 incubator for 72 h, 10 μL of 5% MTT solution was added to each well, and the plate was incubated in a 37℃, 5% CO2 incubator for another 4 h. Then, 100 μL of triplet solution was added to each well, and the 96-well plate was placed in a 37℃, 5% CO2 incubator overnight. The next morning, the absorbance (OD) value of each well at a wavelength of 570 nm was measured using a microplate reader, and the half-inhibitory concentration was calculated.
[0029] The results are as follows Figure 1 As shown in Figure A, different concentrations of Xie Ting Feng capsules were applied to different leukemia cell lines for 72 hours. The half-maximal inhibitory concentrations (WMCs) for HEL, K562, KG-1a, and Jurkat cells were 1.51±0.88 μg / mL, 1.86±0.12 μg / mL, 2.89±0.78 μg / mL, and 1.22±0.19 μg / mL, respectively, all showing good inhibitory effects. The WMC for normal human hepatocytes HL-7702 was greater than 10 mg / mL. Because HEL cells are a classic cell model for studying erythroleukemia, human erythroleukemia cells (HEL) were selected as the main cell type for this study.
[0030] 2. Effects of XTF Capsules on Human Erythroleukemia Cells (HEL) Human erythroleukemia cells HEL in logarithmic proliferation phase were diluted with RPMI 1640 medium containing 10% FBS, inoculated in 96-well plates at a density of 8000 cells / well in 90 μL, and 100 μL of sterilized double distilled water was added to each well every four weeks. The 96-well plates were placed in a 37℃, 5% CO2 incubator for 4 h, and then 10 μL of Xiesheng Capsule solution was added to each well as a treatment group at a concentration of 1.25 mg / mL, 2.50 mg / mL, and 5.00 mg / mL, respectively. Another control group (NC) was set up, in which 10 μL of RPMI-1640 serum-free medium was added to each well. Each group had three replicate wells, which were placed in a 37℃, 5% CO2 incubator. After 24 h, 48 h, and 72 h of treatment, the cell morphological changes were observed and photographed under a microscope, and then 10 μL of 5% MTT solution was added to each well. The plates were incubated in a 37℃, 5% CO2 incubator for 4 h, and then 100 μL of trihydrochloride was added to each well, which was incubated overnight in a 37℃, 5% CO2 incubator. The next morning, the absorbance (OD) value of each well at 570 nm was measured by a microplate reader, and the cell survival rate was calculated. Cell survival rate = control group OD value / control group OD value x 100%.
[0031] The results are shown in Figure 1 B, Figure 1 C. Xiesheng Capsule significantly inhibited the proliferation of human erythroleukemia cells HEL, and had a time- and concentration-dependent effect. When the drug concentration of Xiesheng Capsule acting on human erythroleukemia cells HEL was 5.00 mg / mL, the inhibition rate was 56.15% at 24 h, 77.74% at 48 h, and 85.48% at 72 h, showing a time-dependent effect ( Figure 1 B). Compared with the control group, after 24 h, 48 h, and 72 h of Xiesheng Capsule treatment, the number of cells decreased, and the cells were broken and shriveled ( Figure 1 C).
[0032] 3. Effect of Xiesheng Capsule-containing serum (XTFs) on human erythroleukemia cells HEL HEL cells were diluted with RPMI-1640 medium without FBS and counted, and then were inoculated into 96-well plates at a density of 8000 cells / well. After being cultured in a 37℃, 5% CO2 incubator for 4 h, different concentrations (5%, 10%, 20%) of rat serum containing Xiesheng capsules were added as treatment groups, and the final volume of serum in each group was adjusted to be consistent by supplementing normal rat serum. Normal rat serum was used as a control group (NC group). Each concentration had 3 replicate wells, which were placed in the incubator for 48 h or 72 h. Then, the morphological changes of the cells were observed and photographed under a microscope. Subsequently, 10 μL of 5% MTT solution was added to each well, and the plate was incubated in a 37℃, 5% CO2 incubator for 4 h. Then, 100 μL of trihydrochloride was added to each well, and the plate was incubated overnight in a 37℃, 5% CO2 incubator. The next morning, the absorbance (OD) value of each well at 570 nm was measured using a microplate reader, and the cell survival rate was calculated.
[0033] The results are shown in Figure 2 Compared with the control group, after 48 h and 72 h of treatment with rat serum containing Xiesheng capsules, the number of cells decreased, and the cells were broken and shriveled (A) as the concentration of the drug increased. Figure 2 Compared with the control group, when the concentration of rat serum containing Xiesheng capsules was 20%, the survival rates of HEL cells treated for 48 h and 72 h were 74.22% and 48.56%, respectively (B). Figure 2
[0034] 4. Flow cytometry detection of cell cycle HEL cells in the logarithmic growth phase were inoculated into 6-well plates at a density of 3×10 5 After being cultured in a 37℃, 5% CO2 incubator for 4 h, different concentrations (5%, 10%, 20%) of rat serum containing Xiesheng capsules were added as treatment groups, and the final volume of serum in each group was adjusted to be consistent by supplementing normal rat serum. Normal rat serum was used as a control group (NC group). After the treatment, the cells were collected and washed once with pre-cooled PBS. The supernatant was discarded after centrifugation, and 0.5 mL of pre-cooled 70% ethanol aqueous solution was added to fix the cells at 4℃ for 4 h. Then, the fixed cells were transferred to -20℃ overnight. After removing the ethanol by centrifugation, the cells were washed once with PBS and stained with iodinated propylidene (PI) staining solution prepared according to the instructions for 30 min in the dark. After staining, the cells were washed with PBS and filtered through a 300-mesh screen to prepare a single-cell suspension. The cell cycle distribution was detected using a flow cytometer.
[0035] The results are shown in Figure 3 As shown, the rat serum containing Diercheping capsules could block the cell cycle of human erythroleukemia cells HEL at G1 phase in a dose-dependent manner.
[0036] 5. Flow cytometry detection of cell apoptosis Human erythroleukemia cells HEL in logarithmic growth phase were inoculated in 6-well plates at a density of 3 x 10 5 per well, and were placed in a 37°C, 5% CO2 incubator for 4 h. Then, rat serum containing Diercheping capsules in different concentrations (5%, 10%, and 20%) was added as a treatment group, and the final volume of serum in each group was adjusted to be consistent by supplementing normal rat serum. The cells were continuously cultured for 48 h or 72 h, with normal rat serum as a control group (NC group). After the treatment, the cells were collected and washed once with pre-cooled PBS. After washing, the cells were centrifuged at 1500 rpm for 3 min, and the supernatant was discarded. According to the method of the apoptosis kit, the cells were resuspended with 100 μL of 1 x Binding Buffer, and 1.5 μL of Annexin V-FITC and propidium iodide (PI) staining solution was added, respectively. After mixing, the cells were incubated on ice for 15 min in the dark. Finally, the cells were resuspended with 200-400 μL of 1 x Binding Buffer, and flow cytometry was used for detection. By analyzing the double staining signals of Annexin V-FITC and PI, the apoptosis rate of cells in each group was quantitatively analyzed.
[0037] The results are shown in Table 1. Figure 4 Compared with the control group, the rat serum containing Diercheping capsules could significantly induce apoptosis of human erythroleukemia cells HEL in a time- and dose-dependent manner.
[0038] In the above experiments, each experiment was independently repeated three times, and the experimental data were expressed as mean ± standard deviation (n = 3, * P < 0.05, ** P < 0.01, *** P < 0.001, compared with the control group). P P P
[0039] 6. Therapeutic effect of Diercheping capsules on leukemia mice Fried mouse leukemia virus (F-MuLV) was collected: NIH3T3 cells were recovered, cultured in DMEM medium containing 10% FBS, and expanded in large quantities. When the cell density reached about 80%, 6 mL of serum-free DMEM medium was replaced, and the cells were cultured for another 48 h to collect the virus supernatant. The collected supernatant was centrifuged at 2000 rpm for 5 min to remove cell debris, and then filtered with a 0.22 μm filter to remove bacteria. After aliquoting, the sample was stored at -80°C for later use.
[0040] F-MuLV-induced leukemia mouse model: Balb / c mice were injected with F-MuLV in the abdominal cavity within 48 h after birth for modeling, 120 μL per mouse, and at 4 weeks, they were randomly divided into a Model group, a vincristine group (VCR group, a positive drug control group), a low-dose Xiteng capsules group (XTF-L group), a medium-dose Xiteng capsules group (XTF-M group), and a high-dose Xiteng capsules group (XTF-H group), with another group of normal Balb / c mice (Normal Control group, abbreviated as NC group) as a negative control, 10 mice in each group, half male and half female, and the drug administration started at 6 weeks. The administration method was as follows: the XTF-L group, the XTF-M group, and the XTF-H group were administered by gavage, and the mouse dosage was converted from the human dosage according to the instructions, i.e., the XTF-L group: 0.6 g / kg / d, the XTF-M group: 1.2 g / kg / d, and the XTF-H group: 1.8 g / kg / d, with 200 μL of gavage per 20 g of mice; the VCR group was converted from the human dosage according to the instructions, i.e., the VCR group: 0.5 mg / kg, with 100 μL of intraperitoneal injection per 20 g of mice; the Model group and the NC group were administered with 200 μL of normal saline per 20 g of mice by gavage once a day, and the sample was taken after 4 weeks of continuous administration. The blood volume ratio of the mice was detected; the weights of the heart, liver, spleen, lung, and kidney were measured; the mouse spleen cells and bone marrow cells were taken, and the cells were stained with CD71 and TER119 antibodies in the dark for 30 minutes, then resuspended after washing, and the expression of CD71 and TER119 in each cell population was detected by flow cytometry; the serum was separated for detection of liver and kidney function, and the spleen tissue was taken for pathological section examination. Figure 5 The results showed that compared with the NC group, the liver and kidney indicators of the mice in the Model group were abnormal, and the low-, medium-, and high-dose Xiteng capsules had no effect on the liver and kidney function of the mice. Compared with the Model group, the Xiteng capsules reduced the weight of the spleen of the leukemia mice, thereby reducing the burden on the spleen (see Figure 6 A, B); compared with the Model group, the Xiteng capsules prolonged the survival time of the leukemia mice (see Figure 6 C) and increased the blood volume ratio of the leukemia mice (see Figure 6 D); compared with the NC group, the mice in the Model group had increased liver and lung weights, while the low-, medium-, and high-dose Xiteng capsules significantly reduced the weights compared with the Model group (see Figure 5 E, F), and there was no significant change in the weights of the heart and kidney (see Figure 6 G, H). In the mouse spleen and bone marrow, compared with the Model group, the Xiteng capsules reduced the expression of CD71 + cell population, promoted the differentiation of immature cells to Ter119 + cell population, and improved the anemia symptoms of the mice (see Figure 7 and Figure 8). Compared with the Model group, Xiaozheng Capsule reduced the infiltration of leukemic cells in the spleen of mice and restored the structure of the spleen (see Figure 9 In summary, Xiaozheng Capsule can effectively treat leukemic mice.
[0041] From the above results, it can be seen that Xiaozheng Capsule has potential value for the development of drugs for the prevention and treatment of leukemia.
Claims
1. The application of Xietingfeng capsules in the preparation of drugs for treating leukemia, wherein the leukemia is any one or more of acute lymphoblastic leukemia, acute myeloid leukemia, and chronic myeloid leukemia.
2. The application of the Xietingfeng capsules according to claim 1 in the preparation of drugs for treating leukemia, characterized in that: The drug is any one or more of the following: drugs that inhibit leukemia cell viability, drugs that inhibit leukemia cell proliferation, and drugs that induce leukemia cell apoptosis.
3. The application of the Xietingfeng capsules according to claim 2 in the preparation of drugs for treating leukemia, characterized in that: In the drug for inhibiting the activity of leukemia cells, the leukemia cells are any one or more of the following: human acute myeloid leukemia cells KG-1a, human erythroleukemia cells HEL, human chronic myeloid leukemia cells in the blast crisis phase K562, and human acute T-lymphocytic leukemia cells Jurkat.
4. The application of the Xietingfeng capsules according to claim 2 in the preparation of drugs for treating leukemia, characterized in that: In the drugs for inducing apoptosis of leukemia cells and drugs for inhibiting the proliferation of leukemia cells, the leukemia cells are human erythroleukemia cells (HEL).
5. The use of the Xietingfeng capsules according to any one of claims 1 to 4 in the preparation of drugs for treating leukemia, characterized in that: The drug is prepared directly from Xie Ting Feng capsules into a drug for treating leukemia, or in combination with other drugs for treating leukemia into a compound preparation, or in combination with a pharmaceutically acceptable carrier into a drug for treating leukemia.
6. The application of the Xietingfeng capsules according to claim 5 in the preparation of drugs for treating leukemia, characterized in that: The drug is in a pharmaceutically permissible oral or injectable form, or in a form manufactured using modern technology.